Management of anti-allogeneic antibody elimination by apheresis in living donor liver transplantation.
In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO-blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO-blood type incompatible recipients were administered anti-CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre-existing anti-A and/or anti-B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection.
Kawagishi
Naoki
N
Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai, Japan. kawan@mail.tains.tohoku.ac.jp
Takeda
Ikuo
I
Miyagi
Shigehito
S
Satoh
Kazushige
K
Akamatsu
Yorihiro
Y
Sekiguchi
Satoshi
S
Fujimori
Keisei
K
Sato
Toshinobu
T
Satomi
Susumu
S
D000017:ABO Blood-Group System / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D001787:Blood Group Incompatibility / Q000628:therapy*; D001788:Blood Grouping and Crossmatching; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000302:isolation & purification*; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000379:methods*
D000017:ABO Blood-Group System; D007518:Isoantibodies